Ann: Presentation: Phase 2 study of SNT-5505 in myelofibrosis, page-46

https://www.fiercepharma.com/pharma/novartis-shutter-2-morphosys-sites-lay-330-staffers-post-buyout-consolidation

Not looking great for pelabresib....OUCH!

A perfect storm is brewing for Syntara. The $2.9 billion US purchase by Novarits just shows you how desperate some of the big players are to keep a large piece of the market with Jafaki patents expiring in 2028.

My money is still on BMS. They have their own patent issues, roughly 60% of their revenue is heading to the patent cliff.

https://www.fiercepharma.com/special-report/top-15-blockbuster-patent-expirations-coming-decade

Here's some of their big drugs with patents expiring in the short term.

Revlimid- 2025-2026
Eliquis- 2027-2029
Opdivo- 2028

https://www.livewiremarkets.com/wires/61584

Frazis interview up on livewire.

Syntara shareholders own 100% of the drugs that we have in the clinic. It only becomes apparent at the end stage, when the amount of life left on a patent has a huge impact on value.

The number of times I've sat there with big pharma companies and they look at you across the table and they sort of tense up and they say, how much patent is left?

They’re expecting a bad number, and are pleasantly pleasant relieved when they hear how much we’ve got. Because for them, every extra year of life on a patent adds a huge amount to the net present value of the of the asset, and allows both us and them internally to argue for a higher price.


Here's another part of the interview that caught my attention.

One of them is in low risk MDS, the other one's in high risk.

So 12 months from now, some suggestion of efficacy in those two diseases will, I think, more than double the value of the drug to a big pharma company.